This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Medical IPOs Sustain Discount Trend

Last year was an active one for medical IPOs, and this year looks likely to keep pace.

There were 36 medical companies that went public in 2006, the third-largest number since 1999 when IPO-tracking firm Renaissance Capital started keeping records.

However, 78% of those medical companies went public at a discount to insiders' hopes and underwriters' expectations -- the worst performance ever for medical IPOs, says Renaissance Capital. By contrast, only 32% of last year's 162 non-medical IPOs went public at discounted prices.

Renaissance Capital defines a discount as the difference between an IPO's offer price and the midpoint of the price range first pitched by underwriters. For example, if a company seeks a range of $9 to $11 a share and it goes public at $5, the discount is 50%.

Medical IPOs, especially biotech offerings, are notorious for discounts. Even in 2000, the best year for medical IPOs, 44% of 80 public offerings were discounted.

Last year, "investors' risk tolerance may not have changed, but they wanted a bigger reward," says Melanie Hase, a vice president at Renaissance Capital. In this case, a bigger reward translates into a discounted offer price because investors won't pay an underwriter's sticker price.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
WCRX $0.00 0.00%
ACOR $33.72 -5.20%
ARAY $8.88 2.00%
ATEC $1.43 5.90%
CRDC $0.61 4.90%

Markets

DOW 18,194.45 -19.97 -0.11%
S&P 500 2,112.64 +1.90 0.09%
NASDAQ 4,982.8530 -5.0370 -0.10%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs